Poland· PL-100514682
Vyloy
A other monoclonal antibodies and antibody drug conjugates product containing zolbetuximab, registered in Poland by Astellas Pharma Europe B.V.. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Zolbetuximab is registered in 5 of 19 countries.
Countries holding a registration under ATC L01FX (other monoclonal antibodies and antibody drug conjugates), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 4 of them publish a price we can compare per daily dose
Zolbetuximab · ATC L01FX
5 / 19 countries
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Zolbetuximab
- Manufacturer
- Astellas Pharma Europe B.V.
- Country
- Poland (PL)
- ATC code
- L01FX
- ATC class
- Other monoclonal antibodies and antibody drug conjugates
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991566111
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Zolbetuximab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumVyloy 300 mgAstellas Pharma Europe
- SwitzerlandVyloy 300 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAstellas Pharma AG
- CzechiaVYLOYAstellas Pharma Europe B.V., Leiden
- SpainVYLOY 300 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAstellas Pharma Europe B.V.
- FinlandVyloyAstellas Pharma Europe B.V.
- United KingdomVyloy 300mg powder for concentrate for solution for infusion vialsAstellas Pharma Ltd
- NorwayVyloyAstellas Pharma Europe B.V
- SwedenVyloy 300 mg Pulver till koncentrat till infusionsvätska, lösningAstellas Pharma Europe BV
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vyloy
- Liechtenstein · Vyloy
- Norway · Vyloy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/08d36245-c5ff-4d59-9b9f-e08fc74f437a GET /v1/drugs/08d36245-c5ff-4d59-9b9f-e08fc74f437a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "300 mg",
"packaging": "05909991566111 ¦ Rpz ¦ EU/1/24/1856/003 ¦ 160732\n1 fiol. 50 ml",
"substance": "Zolbetuximab 300 mg",
"common_name": "Zolbetuximab",
"pl_product_id": "100514682",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about zolbetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.